Cencora
COR · What the business does, what can go wrong, and how options sellers approach it
What it does
Cencora is a pharmaceutical distributor. It buys medicines from manufacturers and delivers them to pharmacies, hospitals, physician practices and other healthcare providers. It is one of the three large wholesalers that dominate US drug distribution.
Beyond core distribution, the company has several related businesses: specialty drug distribution and services for physician practices, commercialization support for drug and device makers, global specialty logistics through World Courier, animal health distribution through MWI Animal Health, and wholesale operations in Europe through Alliance Healthcare.
How it makes money
Distribution is a high-volume, thin-margin business. Cencora earns a small spread between what it pays manufacturers and what it charges customers, plus fees for services such as logistics, inventory management, data and manufacturer support. Revenue is large, but profit per dollar of sales is small, so efficiency and scale matter.
Specialty drugs, which are complex and often expensive, tend to be a growth area.
Why investors own it
Drug distribution is a necessary link in the healthcare supply chain, and demand tends to be steady through economic cycles. Only a few players have the scale, logistics and manufacturer relationships to compete. Growth in specialty medicines and an aging population are long-term tailwinds. The company has also historically returned cash through dividends and share buybacks.
What can go wrong
- Pricing pressure from large customers, reimbursement changes and generic price swings can squeeze thin margins.
- Regulation, drug pricing reform and litigation (including opioid-related legal matters across the industry) are ongoing risks.
- Customer concentration: a few large buyers account for a big share of sales.
- International and currency exposure, plus acquisitions, add complexity.
What to watch
- Segment operating income, especially US healthcare and international
- Specialty product growth
- Gross margin and operating margin trends
- Customer contract renewals or losses
- Drug pricing and reimbursement policy changes
- Cash flow, debt levels and capital return policy
- Legal and settlement developments
Options income angle
Options on COR trade across many expirations, but volume is lighter than for the most active large caps, so spreads can be wider. Implied volatility tends to be modest, rising around earnings and drug pricing or policy headlines. One caution for premium sellers: a sharp post-earnings or regulatory move can overwhelm the small premium collected.
What the latest 10-K says
A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended September 30, 2025, filed November 25, 2025. Figures are as the filing reports them. Read the filing on SEC.gov
The filing in brief
Cencora reported fiscal 2025 revenue growth of $27.4 billion, or 9.3%, and operating income growth of 20.8%, even after a goodwill write-down of $723.9 million at its PharmaLex consulting business. The filing stresses how dependent the company is on Walgreens and Boots, which were bought by the private equity firm Sycamore Partners on August 28, 2025. It also stresses the $4.3 billion opioid settlement liability and a wave of drug-pricing policy changes.
How the business did
- Revenue rose $27.4 billion, or 9.3%. U.S. Healthcare Solutions grew 9.7% on higher unit volume, more specialty drug sales to health systems and physician practices, and sales of GLP-1 diabetes and weight-loss products that rose $7.7 billion, or 26.9%. International Healthcare Solutions grew 6.1%.
- Gross profit increased $1,568.5 million, or 15.8%, helped by the January 2025 acquisition of RCA, a retina specialist management company, and larger gains from antitrust settlements. International operating income fell 9.1% on weaker specialty logistics and consulting.
- Unusual items: the PharmaLex goodwill impairment (a write-down of acquisition value; $418.0 million the prior year), a $113.5 million impairment of an equity investment, and interest expense, net up 85.7% after debt was raised to fund RCA. The effective tax rate was 30.6% versus 24.2%, because the impairments are largely not tax deductible.
- Operating activities provided $3.9 billion of cash. The company paid $437.1 million in dividends and $435.5 million for share repurchases, and spent $3.9 billion on RCA.
Risks specific to this company
- Customer concentration: Walgreens and Boots were approximately 25% of revenue and approximately 38% of accounts receivable, net. Evernorth was approximately 13% of revenue, and the top ten customers were approximately 66%.
- Walgreens ownership change: The new owners may seek changes to the relationship or accelerate a plan to close approximately 1,200 U.S. stores. The U.S. agreements run until 2029 and the Boots agreement until 2031.
- Opioid litigation: The accrued liability is $4.3 billion, payable over 13 years, with $416.0 million expected before September 30, 2026. The company cannot estimate the possible loss on matters outside the accrual, and losses could reduce capital returned to stockholders.
- Drug pricing policy: Executive Order 14297 on most-favored-nation pricing could push manufacturers toward direct-to-consumer sales that bypass wholesalers. A CMS rule finalized in October 2025 tightens the exemption for distribution service fees in Medicare Part B price calculations.
- 340B program disputes: Manufacturer limits on contract pharmacies and approved pilot rebate programs could hurt customers. The rebates may also replace chargeback mechanisms (discount credits to wholesalers) that the company administers.
- Acquisitions and tariffs: RCA and the $718.4 million OneOncology investment may not meet expectations. PharmaLex faces weaker demand, and U.S. tariffs could add costs or disrupt supply.
What management is watching
- Reporting changes: Starting in the first quarter of fiscal 2026, results will be reported as U.S. Healthcare Solutions, International Healthcare Solutions, and Other. Other holds MWI Animal Health, Profarma, U.S. Consulting Services, and parts of PharmaLex, businesses for which management has begun exploring strategic alternatives.
- Growth drivers: Management points to GLP-1 drug use, new brand therapies and vaccines, generics and biosimilars arriving as patents expire, price inflation and deflation, and downward pressure on reimbursement rates.
- Customer contracts: An oncology customer's contract was terminated in June 2025. No key contracts are scheduled to expire over the next twelve months.
- Spending: Capital expenditures are expected to be approximately $900 million in fiscal 2026, for the distribution network and technology.
- Capital return and working capital: The quarterly dividend rose to $0.600 in November 2025 from $0.550, and $882.2 million remained on the share repurchase authorization. Management tracks days sales outstanding (27.9), days inventory on hand (27.0), and days payable outstanding (59.6).
What the latest 10-Q says
A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended June 30, 2026, filed August 5, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The quarter in brief
Cencora's revenue rose 5.1% in the quarter ended June 30, 2026, helped by strong sales of GLP-1 drugs (the diabetes and weight-loss class). Gross profit rose 24.1% and operating income rose 29.1%, mostly because of the February 2026 acquisition of OneOncology and a credit from dismissed opioid litigation. Borrowing to fund that deal pushed net interest expense sharply higher.
How the business did
- Revenue: Revenue increased by $4.1 billion, or 5.1%, for the quarter and by $11.4 billion, or 4.8%, for the nine months. U.S. Healthcare Solutions grew 4.9%, with GLP-1 sales up $2.3 billion, or 25.5%. Lower brand drug prices, the loss of an oncology customer and lower sales to a large mail order customer offset part of that. International Healthcare Solutions grew 5.9%, led by European distribution.
- Profit: Gross profit increased by $700.1 million, or 24.1%, helped by OneOncology and higher LIFO credits. LIFO is an inventory accounting method, and the credits here came mainly from falling manufacturer prices on some brand drugs. U.S. gross margin was 3.17%, up 63 basis points (a basis point is one hundredth of a percentage point), even though GLP-1s carry lower margins. Operating income rose 15.8% for the nine months.
- Unusual items: The quarter included a $102.0 million reduction of opioid liability after litigation was dismissed. The nine months included a $249.5 million impairment tied to the U.S. Consulting Services business, which was divested in April 2026, and a $1.1 billion gain on the OneOncology investment. Net interest expense increased by $58.9 million, or 72.0%, for the quarter.
- Cash and capital return: Operating cash flow was $1.7 billion for the nine months, versus $0.7 billion a year earlier. The company spent $1.0 billion on share purchases and paid $360.6 million in dividends. In May 2026 the board authorized a new $2.0 billion buyback, with $1,882.2 million available at quarter end.
What management is watching
- Spending: The company expects to invest approximately $900 million in capital expenditures during fiscal 2026, for distribution network expansion and technology. Other commitments include $652 million for an enterprise resource planning system upgrade in U.S. Healthcare Solutions.
- Opioid settlements: The accrued liability is $4.2 billion, to be paid over the next 13 years, with $396.2 million estimated before June 30, 2027. Management says the payments are not expected to affect its ability to pay dividends.
- Funding: In July 2026 the company repaid a $400 million term loan in full and amended its revolving credit facility, raising it to $7.0 billion and extending it to July 2031. It also cut its receivables securitization facility to $1.0 billion.
- Growth drivers and metrics: Management points to GLP-1 demand, new generics and biosimilars, and drug pricing as factors for future revenue. It says no key contracts are scheduled to expire over the next twelve months. It tracks days sales outstanding, days inventory on hand and days payable outstanding to judge working capital.
Follow COR in Kortex
The Kortex app shows COR's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.